Quart Barry D 4

4 · Kiniksa Pharmaceuticals International, plc · Filed Jun 11, 2025

Form 4

Period: 2025-06-09

Director

Transactions

Sale
Class A Ordinary Share
2025-06-09$30.26/sh−6,900$208,794→ 12,546 total
Sale
Class A Ordinary Share
2025-06-10$30.36/sh−8,212$249,316→ 12,546 total
Exercise/Conversion
Class A Ordinary Share
2025-06-11$3.80/sh+12,336$46,877→ 24,882 total
Exercise/Conversion
Class A Ordinary Share
2025-06-09$3.80/sh+6,900$26,220→ 19,446 total
Exercise/Conversion
Class A Ordinary Share
2025-06-10$3.80/sh+8,212$31,206→ 20,758 total
Exercise/Conversion
Share Option
2025-06-09−6,900→ 20,548 total
Exercise: $3.80Exp: 2027-06-28→ Class A Ordinary Share (6,900 underlying)
Exercise/Conversion
Share Option
2025-06-10−8,212→ 12,336 total
Exercise: $3.80Exp: 2027-06-28→ Class A Ordinary Shares (8,212 underlying)
Sale
Class A Ordinary Share
2025-06-11$30.39/sh−12,336$374,891→ 12,546 total
Exercise/Conversion
Share Option
2025-06-11−12,336→ 0 total
Exercise: $3.80Exp: 2027-06-28→ Class A Ordinary Shares (12,336 underlying)

Footnotes (3)

[F1]This transaction was executed in multiple trades through a broker-dealer at prices ranging between $30.00 and $30.52. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
[F2]This transaction was executed in multiple trades through a broker-dealer at prices ranging between $30.28 and $30.5801. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
[F3]The option is fully vested and exercisable.

Documents

1 file